ArticleChemotherapy research and practice2012
Deciphering the role of insulin-like growth factor-I receptor in trastuzumab resistance.
Article in Chemotherapy research and practice, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Metabolic hallmarks of trastuzumab resistance.Expert opinion on therapeutic targets · 2025Review
- Molecular Assessment of HER2 to Identify Signatures Associated with Therapy Response in HER2-Positive Breast Cancer.Cancers · 2022Article
- Nanotechnology in the development of small and large molecule tyrosine kinase inhibitors and immunotherapy for the treatment of HER2-positive breast cancer.Journal of cancer & metastasis research · 2022Article
- IGF1R constitutive activation expands luminal progenitors and influences lineage differentiation during breast tumorigenesis.Developmental biology · 2020Article
- Article
- ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1).PloS one · 2017Article
- Lack of interaction between ErbB2 and insulin receptor substrate signaling in breast cancer.Cell communication and signaling : CCS · 2016Article
- Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance.Genes & diseases · 2015Article
- Role of IGF1R in Breast Cancer Subtypes, Stemness, and Lineage Differentiation.Frontiers in endocrinology · 2015Review
- The impact of IGF-1R expression on the outcomes of patients with breast cancer: a meta-analysis.OncoTargets and therapy · 2015Article
- Association of insulin-like growth factor-I receptor polymorphism with colorectal cancer development.Molecular biology reports · 2014Article
- IGF-1R peptide vaccines/mimics inhibit the growth of BxPC3 and JIMT-1 cancer cells and exhibit synergistic antitumor effects with HER-1 and HER-2 peptides.Oncoimmunology · 2014Article
- Positive expression of insulin-like growth factor-1 receptor is associated with a positive hormone receptor status and a favorable prognosis in breast cancer.Journal of breast cancer · 2014Article
- Differential expression of the insulin-like growth factor receptor among early breast cancer subtypes.PloS one · 2014Article
- A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer.Breast cancer research and treatment · 2013Article
- Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer.ISRN oncology · 2012Article
- Resistance to HER2-targeted therapies: a potential role for FOXM1.Breast cancer managementArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Resistance to the HER2-targeted antibody trastuzumab is a major clinical concern in the treatment of HER2-overexpressing metastatic breast cancer. Increased expression or signaling of the insulin-like growth factor-I receptor (IGF-IR) has been reported in a subset of cell lines and clinical samples derived from trastuzumab-resistant breast cancers. Genetic and pharmacologic inhibition of IGF-IR signaling has been shown to improve response to trastuzumab in trastuzumab-naïve and trastuzumab-resistant models. In this paper, we will discuss the role of IGF-IR signaling in trastuzumab resistance. Further, we will discuss cotargeting IGF-IR and HER2 as a potential therapeutic strategy for HER2-over-expressing breast cancers that have progressed on trastuzumab treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.